AMPH on Nasdaq
Amphastar Pharmaceuticals, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Compare with SUPERNUS PHARMACEUTICALS, INC., Pacira BioSciences, Inc. or Emergent BioSolutions, or pick any stock.
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Key numbers, fiscal 2025
49.5%Gross margin3
19.5%Operating margin3
13.6%Net margin3
-1.7%Revenue growth, 20253
12.4%Return on equity3
0.79×Debt to equity3
$121.2MFree cash flow3
What sells
Revenue by product, business segment and region, as the company reports it to the SEC.
Regions
United States brought in 95% of the revenue Amphastar Pharmaceuticals, Inc. broke down this way in fiscal 2025.
Regions by year
| Regions | 2023 | 2024 | 2025 |
|---|---|---|---|
| United States | $635.2M | $707.7M | $681.4M |
| France | $4.7M | $19.9M | $35.3M |
| China | $4.5M | $4.3M | $3.2M |
Where the money goes
Where each dollar of revenue went, fiscal 2025
- Cost of revenue51¢$363.8M
- Research and development12¢$85.8M
- Other costs20¢$146.6M
- Income tax4¢$25.5M
- Profit14¢$98.1M
Out of $719.9M in revenue.3
Where each dollar of operating cash went, fiscal 2025
- Capital spending22¢$34.9M
- Share buybacks48¢$75.6M
- Kept or used elsewhere29¢$45.6M
Out of $156.1M of cash from operations.3
Financial statements
Every line of the income statement in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Revenues | $719.9M | $732.0M | $644.4M |
| Cost of revenues | $363.8M | $358.1M | $293.3M |
| Gross profit | $356.1M | $373.9M | $351.1M |
| Selling, distribution, and marketing | $43.9M | $37.8M | $28.9M |
| General and administrative | $85.9M | $56.7M | $51.5M |
| Research and development | $85.8M | $73.9M | $73.7M |
| Total operating expenses | $215.7M | $168.4M | $154.1M |
| Income from operations | $140.4M | $205.4M | $197.0M |
| Interest income | $8.7M | $10.6M | $5.5M |
| Interest expense | -$25.5M | -$30.3M | -$27.2M |
| Other income (expenses), net | $23.0K | $4.1M | -$3.9M |
| Total non-operating income (expenses), net | -$16.8M | -$15.7M | -$25.6M |
| Income before income taxes | $123.6M | $189.8M | $171.4M |
| Income tax provision | $25.5M | $29.7M | $31.8M |
| Income before equity in losses of unconsolidated affiliate | $98.1M | $160.1M | $139.5M |
| Equity in losses of unconsolidated affiliates | -$573.0K | -$2.0M | |
| Net income | $98.1M | $159.5M | $137.5M |
| Basic | $2.10 | $3.29 | $2.85 |
| Diluted | $2.03 | $3.06 | $2.60 |
| Basic (in shares) | 46.7M shares | 48.4M shares | 48.3M shares |
| Diluted (in Shares) | 48.2M shares | 52.1M shares | 53.0M shares |
Every line of the balance sheet in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $170.2M | $151.6M | |
| Restricted cash | $235.0K | $235.0K | |
| Short-term investments | $112.6M | $70.0M | |
| Restricted short-term investments | $2.2M | $2.2M | |
| Accounts receivable, net | $143.6M | $136.3M | |
| Inventories | $176.9M | $153.7M | |
| Income tax refunds and deposits | $17.2M | $1.7M | |
| Prepaid expenses and other assets | $13.2M | $18.2M | |
| Total current assets | $636.0M | $534.1M | |
| Property, plant, and equipment, net | $310.6M | $297.3M | |
| Finance lease right-of-use assets | $221.0K | $383.0K | |
| Operating lease right-of-use assets | $42.9M | $46.9M | |
| Goodwill and intangible assets, net | $566.0M | $590.7M | |
| Long-term investments | $11.0M | ||
| Other assets | $31.1M | $26.0M | |
| Deferred tax assets | $42.5M | $71.1M | |
| Total assets | $1.6B | $1.6B | |
| Accounts payable and accrued liabilities | $148.3M | $157.1M | |
| Income taxes payable | $239.0K | $9.7M | |
| Current portion of long-term debt | $1.6M | $234.0K | |
| Current portion of operating lease liabilities | $7.9M | $6.8M | |
| Total current liabilities | $158.2M | $173.8M | |
| Long-term reserve for income tax liabilities | $5.9M | $7.0M | |
| Long-term debt, net of current portion and unamortized debt issuance costs | $608.7M | $601.6M | |
| Long-term operating lease liabilities, net of current portion | $37.7M | $41.9M | |
| Other long-term liabilities | $30.0M | $20.9M | |
| Total liabilities | $840.5M | $845.2M | |
| Common stock: par value $0.0001; 300,000,000 shares authorized; 61,779,883 and 45,645,497 shares issued and outstanding, respectively, as of December 31, 2025 and 60,847,124 and 47,617,691 shares issued and outstanding, respectively, as of December 31, 2024 | $6.0K | $6.0K | |
| Additional paid-in capital | $535.4M | $505.4M | |
| Retained earnings | $666.9M | $568.8M | |
| Accumulated other comprehensive loss | -$5.3M | -$9.2M | |
| Treasury stock | -$408.1M | -$332.7M | |
| Total stockholders' equity | $788.8M | $732.3M | $639.4M |
| Total liabilities and stockholders' equity | $1.6B | $1.6B | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized | 20.0M shares | 20.0M shares | |
| Preferred stock, shares issued | 0 shares | 0 shares | |
| Preferred Stock, Shares Outstanding | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock; shares authorized | 300.0M shares | 300.0M shares | |
| Common stock; shares issued | 61.8M shares | 60.8M shares | |
| Common stock; shares outstanding | 45.6M shares | 47.6M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.3
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net income | $98.1M | $159.5M | $137.5M |
| Loss on disposal of assets | $39.0K | $9.0K | $475.0K |
| Impairment of long-lived assets | $2.7M | ||
| Loss (gain) on interest rate swaps and foreign currency transactions, net | $2.5M | -$2.8M | $5.3M |
| Depreciation of property, plant, and equipment | $31.6M | $28.2M | $25.2M |
| Amortization of intangible assets | $25.0M | $24.7M | $12.8M |
| Operating lease right-of-use asset amortization | $6.5M | $4.2M | $3.7M |
| Amortization of discounts, premiums, and debt issuance costs | $3.4M | $6.0M | $11.4M |
| Equity in losses of unconsolidated affiliate | $573.0K | $2.0M | |
| Share-based compensation expense | $27.3M | $24.4M | $20.2M |
| Changes in reserve for uncertain tax positions | -$1.0M | $891.0K | -$1.2M |
| Changes in deferred taxes, net | $28.7M | -$17.9M | -$12.6M |
| Accounts receivable, net | -$6.4M | -$21.7M | -$26.1M |
| Inventories | -$21.1M | -$48.8M | -$1.7M |
| Prepaid expenses and other assets | -$3.5M | -$10.7M | -$2.7M |
| Income tax refunds, deposits, and payable, net | -$24.8M | $6.8M | -$3.3M |
| Operating lease liabilities | -$5.6M | -$3.8M | -$3.6M |
| Accounts payable and accrued liabilities | -$4.6M | $63.6M | $13.2M |
| Net cash provided by operating activities | $156.1M | $213.4M | $183.5M |
| BAQSIMI acquisition | -$129.0M | -$506.4M | |
| Purchases and construction of property, plant, and equipment | -$34.9M | -$41.0M | -$38.2M |
| Purchase of intangible assets | -$2.2M | ||
| Purchase of investments | -$119.1M | -$76.8M | -$144.6M |
| Maturity of investments | $90.3M | $126.0M | $38.6M |
| Deposits and other assets | -$4.4M | -$4.1M | $1.4M |
| Net cash used in investing activities | -$70.3M | -$124.9M | -$649.1M |
| Proceeds from equity plans, net of withholding tax payments | $2.9M | $11.0M | |
| Proceeds from equity plans, net of withholding tax payments | -$4.8M | ||
| Purchase of treasury stock | -$75.6M | -$85.5M | -$58.1M |
| Debt issuance costs | -$687.0K | -$816.0K | -$25.1M |
| Proceeds from borrowing under lines of credit | $6.2M | $18.4M | |
| Proceeds from Issuance of long-term debt | $845.0M | ||
| Principal payments on long-term debt | -$223.0K | -$8.3M | -$318.7M |
| Net cash provided by (used in) financing activities | -$67.4M | -$81.0M | $454.1M |
| Effect of exchange rate changes on cash | $210.0K | -$190.0K | -$282.0K |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | $18.6M | $7.3M | -$11.8M |
| Deferred payment for BAQSIMI acquisition | $121.7M | ||
| Capital expenditures included in accounts payable | $7.7M | $5.6M | $4.5M |
| Operating lease right-of-use assets in exchange for operating lease liabilities | $2.5M | $18.8M | $10.5M |
| Interest paid, net of capitalized interest | $23.2M | $26.8M | $17.6M |
| Income taxes paid | $22.7M | $40.1M | $49.0M |
Compare Amphastar Pharmaceuticals, Inc. with another company
Recent filings
- Sep 23, 20264
- Sep 21, 2026144
- Sep 17, 20264
- Sep 3, 20264
- Sep 1, 2026144
- Aug 18, 2026144
- Aug 12, 20264
- Aug 11, 2026144
- Aug 11, 20264
- Aug 7, 2026144
- Aug 6, 20268-K
- Aug 6, 202610-Q
- Jul 14, 2026SCHEDULE 13G
- Jul 13, 20268-K
- Jul 13, 20263
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11